Bruno Azevedo Randi, Eder Gatti Fernandes, Hermes Ryoiti Higashino, Marta Heloisa Lopes, Vanderson Geraldo Rocha, Silvia Figueiredo Costa, Ana Marli Christovam Sartori
{"title":"造血干细胞移植后12个月接种麻疹、腮腺炎和风疹疫苗。","authors":"Bruno Azevedo Randi, Eder Gatti Fernandes, Hermes Ryoiti Higashino, Marta Heloisa Lopes, Vanderson Geraldo Rocha, Silvia Figueiredo Costa, Ana Marli Christovam Sartori","doi":"10.1590/S1678-9946202365021","DOIUrl":null,"url":null,"abstract":"<p><p>The measles, mumps and rubella (MMR) vaccine is usually recommended from 24 months after a hematopoietic stem cell transplant (HSCT). Some authors have demonstrated that the MMR vaccination can be safe from 12 months post-HSCT in non-immunosuppressed patients, as recommended by the Brazilian National Immunization Program/Ministry of Health, since 2006. The objectives of this study were to evaluate when patients received MMR vaccine after an HSCT in our care service and if there were reports of any side effects. We retrospectively reviewed the records of HSCT recipients who received at least one MMR dose in our care service, a quaternary teaching hospital in Sao Paulo city, Brazil, from 2017 to 2021. We identified 82 patients: 75.6% (90.1% in the autologous group and 45.1% in the allogeneic group) were vaccinated before 23 months post-transplantation. None reported side effects following the vaccination. Our data support that the MMR vaccination is safe from 12 to 23 months after HSCT.</p>","PeriodicalId":54466,"journal":{"name":"Revista Do Instituto De Medicina Tropical De Sao Paulo","volume":"65 ","pages":"e21"},"PeriodicalIF":1.5000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d6/a1/1678-9946-rimtsp-65-S1678-9946202365021.PMC10027056.pdf","citationCount":"0","resultStr":"{\"title\":\"Measles, mumps and rubella vaccine 12 months after hematopoietic stem cell transplantation.\",\"authors\":\"Bruno Azevedo Randi, Eder Gatti Fernandes, Hermes Ryoiti Higashino, Marta Heloisa Lopes, Vanderson Geraldo Rocha, Silvia Figueiredo Costa, Ana Marli Christovam Sartori\",\"doi\":\"10.1590/S1678-9946202365021\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The measles, mumps and rubella (MMR) vaccine is usually recommended from 24 months after a hematopoietic stem cell transplant (HSCT). Some authors have demonstrated that the MMR vaccination can be safe from 12 months post-HSCT in non-immunosuppressed patients, as recommended by the Brazilian National Immunization Program/Ministry of Health, since 2006. The objectives of this study were to evaluate when patients received MMR vaccine after an HSCT in our care service and if there were reports of any side effects. We retrospectively reviewed the records of HSCT recipients who received at least one MMR dose in our care service, a quaternary teaching hospital in Sao Paulo city, Brazil, from 2017 to 2021. We identified 82 patients: 75.6% (90.1% in the autologous group and 45.1% in the allogeneic group) were vaccinated before 23 months post-transplantation. None reported side effects following the vaccination. Our data support that the MMR vaccination is safe from 12 to 23 months after HSCT.</p>\",\"PeriodicalId\":54466,\"journal\":{\"name\":\"Revista Do Instituto De Medicina Tropical De Sao Paulo\",\"volume\":\"65 \",\"pages\":\"e21\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d6/a1/1678-9946-rimtsp-65-S1678-9946202365021.PMC10027056.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista Do Instituto De Medicina Tropical De Sao Paulo\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1590/S1678-9946202365021\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Do Instituto De Medicina Tropical De Sao Paulo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1590/S1678-9946202365021","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Measles, mumps and rubella vaccine 12 months after hematopoietic stem cell transplantation.
The measles, mumps and rubella (MMR) vaccine is usually recommended from 24 months after a hematopoietic stem cell transplant (HSCT). Some authors have demonstrated that the MMR vaccination can be safe from 12 months post-HSCT in non-immunosuppressed patients, as recommended by the Brazilian National Immunization Program/Ministry of Health, since 2006. The objectives of this study were to evaluate when patients received MMR vaccine after an HSCT in our care service and if there were reports of any side effects. We retrospectively reviewed the records of HSCT recipients who received at least one MMR dose in our care service, a quaternary teaching hospital in Sao Paulo city, Brazil, from 2017 to 2021. We identified 82 patients: 75.6% (90.1% in the autologous group and 45.1% in the allogeneic group) were vaccinated before 23 months post-transplantation. None reported side effects following the vaccination. Our data support that the MMR vaccination is safe from 12 to 23 months after HSCT.
期刊介绍：
The Revista do Instituto de Medicina Tropical de São Paulo (Journal of the São Paulo Institute of Tropical Medicine) is a journal devoted to research on different aspects of tropical infectious diseases. The journal welcomes original work on all infectious diseases, provided that data and results are directly linked to human health.
The journal publishes, besides original articles, review articles, case reports, brief communications, and letters to the editor. The journal publishes manuscripts only in English.
From 2016 on, the Revista do Instituto de Medicina Tropical de São Paulo (Journal of the São Paulo Institute of Tropical Medicine) is published online only, maintaining the free access.
For more information visit:
- http://www.scielo.br/rimtsp
- http://www.imt.usp.br/revista-imt/
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
